{"id":"W4412693759","doi":"10.1093/jacamr/dlaf131","title":"Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)","year":2025,"lang":"en","type":"article","venue":"JAC-Antimicrobial Resistance","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada)","funders":"Biomedical Advanced Research and Development Authority; Wockhardt; Pfizer; U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response","keywords":"Aztreonam; Ceftazidime/avibactam; Medicine; Avibactam; Internal medicine; Randomized controlled trial; Klebsiella pneumoniae; Antibiotics; Gastroenterology; Microbiology; Surgery; Biology; Antibiotic resistance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005303973,0.0004252508,0.0009435418,0.00008742051,0.0003628136,0.00008791743,0.0003225812,0.0002259062,0.00001627969],"category_scores_gemma":[0.001138127,0.000314917,0.0007209833,0.0003190738,0.0004543149,0.00001389802,0.00004486834,0.00009581471,0.000002091845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001159809,"about_ca_system_score_gemma":0.0003252284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001079211,"about_ca_topic_score_gemma":0.0005260591,"domain_scores_codex":[0.997451,0.0003329623,0.0008343862,0.0007767918,0.0001569465,0.000447892],"domain_scores_gemma":[0.9975384,0.0006659333,0.0005350159,0.000899238,0.0002966573,0.00006479212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2300212,0.001048055,0.00004275604,0.00009389657,0.0009967694,0.000002001264,0.0001216119,0.00001834834,0.7559009,0.0001272506,0.0109087,0.0007185703],"study_design_scores_gemma":[0.3248257,0.0006833664,0.00008341324,0.00009655962,0.0007273706,0.00000117589,0.00004969408,0.00003307458,0.6206323,0.00009084815,0.05247898,0.0002975665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766693,0.001695321,0.01436695,0.0006824505,0.0009973759,0.004588888,0.0006631867,0.00003640597,0.0003001396],"genre_scores_gemma":[0.9837611,0.00248077,0.002388298,0.0001975082,0.0002755351,0.0004751704,0.0003309249,0.00005782216,0.01003286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1352686,"threshold_uncertainty_score":0.9999303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01058036266218473,"score_gpt":0.2914676398263794,"score_spread":0.2808872771641947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}